Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

NCT00685776 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1623

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Heart Disease (CHD)
CHD Risk-Equivalent Disease

Interventions

DRUG: anacetrapib
DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC